Laura E M Wisse1, Jeroen de Bresser2, Mirjam I Geerlings3, Yael D Reijmer4, Marileen L P Portegies5, Manon Brundel6, L Jaap Kappelle6, Yolanda van der Graaf7, Geert Jan Biessels6. 1. UMC Utrecht, Julius Center for Health Sciences and Primary Care, Utrecht, The Netherlands; UMC Utrecht, Department of Neurology, Brain Center Rudolf Magnus, Utrecht, The Netherlands. 2. UMC Utrecht, Department of Radiology, Utrecht, The Netherlands. 3. UMC Utrecht, Julius Center for Health Sciences and Primary Care, Utrecht, The Netherlands. Electronic address: m.geerlings@umcutrecht.nl. 4. UMC Utrecht, Department of Neurology, Brain Center Rudolf Magnus, Utrecht, The Netherlands; J. Philip Kistler Stroke Center, MA General Hospital, Harvard Medical School, Boston, USA. 5. Erasmus MC, Department of Epidemiology and Neurology, Rotterdam, The Netherlands. 6. UMC Utrecht, Department of Neurology, Brain Center Rudolf Magnus, Utrecht, The Netherlands. 7. UMC Utrecht, Julius Center for Health Sciences and Primary Care, Utrecht, The Netherlands.
Abstract
AIMS: It has been suggested that in patients with type 2 diabetes mellitus (T2DM), brain atrophy is most pronounced in the hippocampus, but this has not been investigated systematically. The present pooled analysis of three studies examined if hippocampal atrophy is more prominent than global brain atrophy in patients with T2DM relative to controls. METHODS: Data were derived from a cohort study of patients with vascular disease (SMART-Medea (T2DM=120; no T2DM=502)), and from two case-control studies (UDES1 (T2DM=61; controls=30) and UDES2 (T2DM=54; controls=53)). In SMART-Medea and UDES1, hippocampal volume was obtained by manual tracing on 1.5 Tesla (T) MRI scans. Total brain and intracranial volume (ICV) were determined by an automated segmentation method. In UDES2, hippocampal and total brain volume were determined by FreeSurfer and ICV by manual segmentation on 3 T MRI scans. RESULTS: The pooled analyses, adjusted for age and sex, showed a significant negative relation between T2DM and total brain-to-ICV ratio (standardized mean difference=-1.24%, 95% CI: -1.63; -0.86), but not between T2DM and hippocampal-to-ICV ratio (0.00%, 95% CI: -0.01; 0.00) or between T2DM and hippocampal-to-total brain volume ratio (0.01%, 95% CI: -0.01; 0.02). In patients with T2DM no associations were found between brain volume measures and HbA1c or memory. CONCLUSION: Patients with T2DM had greater brain atrophy but not hippocampal atrophy, compared to controls. These findings do not support specific vulnerability of the hippocampus in patients with T2DM.
AIMS: It has been suggested that in patients with type 2 diabetes mellitus (T2DM), brain atrophy is most pronounced in the hippocampus, but this has not been investigated systematically. The present pooled analysis of three studies examined if hippocampal atrophy is more prominent than global brain atrophy in patients with T2DM relative to controls. METHODS: Data were derived from a cohort study of patients with vascular disease (SMART-Medea (T2DM=120; no T2DM=502)), and from two case-control studies (UDES1 (T2DM=61; controls=30) and UDES2 (T2DM=54; controls=53)). In SMART-Medea and UDES1, hippocampal volume was obtained by manual tracing on 1.5 Tesla (T) MRI scans. Total brain and intracranial volume (ICV) were determined by an automated segmentation method. In UDES2, hippocampal and total brain volume were determined by FreeSurfer and ICV by manual segmentation on 3 T MRI scans. RESULTS: The pooled analyses, adjusted for age and sex, showed a significant negative relation between T2DM and total brain-to-ICV ratio (standardized mean difference=-1.24%, 95% CI: -1.63; -0.86), but not between T2DM and hippocampal-to-ICV ratio (0.00%, 95% CI: -0.01; 0.00) or between T2DM and hippocampal-to-total brain volume ratio (0.01%, 95% CI: -0.01; 0.02). In patients with T2DM no associations were found between brain volume measures and HbA1c or memory. CONCLUSION:Patients with T2DM had greater brain atrophy but not hippocampal atrophy, compared to controls. These findings do not support specific vulnerability of the hippocampus in patients with T2DM.
Authors: Jennifer K Ferris; Sue Peters; Katlyn E Brown; Katherine Tourigny; Lara A Boyd Journal: J Cereb Blood Flow Metab Date: 2017-04-12 Impact factor: 6.200
Authors: Michael M Zeineh; Nicola Palomero-Gallagher; Markus Axer; David Gräßel; Maged Goubran; Andreas Wree; Roger Woods; Katrin Amunts; Karl Zilles Journal: Cereb Cortex Date: 2017-03-01 Impact factor: 5.357
Authors: Saima Hilal; Xu Xin; Seow Li Ang; Chuen Seng Tan; Narayanaswamy Venketasubramanian; Wiro J Niessen; Henri Vrooman; Tien Yin Wong; Christopher Chen; Mohammad Kamran Ikram Journal: Medicine (Baltimore) Date: 2015-06 Impact factor: 1.889
Authors: Andrea L C Schneider; Elizabeth Selvin; A Richey Sharrett; Michael Griswold; Josef Coresh; Clifford R Jack; David Knopman; Thomas Mosley; Rebecca F Gottesman Journal: Diabetes Care Date: 2017-09-15 Impact factor: 19.112